-The Economic Times MUMBAI/ BANGALORE/ NEW DELHI: For 100,000 employees in the group, ICICI gets 60-odd sexual harassment complaints in a year. Of this, 30-40% are found to be true. India's second-largest bank by assets does not insist on absolute proof when it comes to allegations of sexual harassment. In case of circumstantial evidence, the person is asked to resign. If there is stronger proof, the person is sacked. ICICI is among...
More »SEARCH RESULT
Total Matching Records found : 283
President Pranab Mukherjee hits out at MNCs for their ‘intent to dodge tax’
-The Times of India NAGPUR: President Pranab Mukherjee on Monday slammed Multinational Companies saying they only looked for oversees locations with an intention to dodge taxes, raising eyebrows at a time when the country is desperately wooing foreign capital to plug a widening current account deficit. Addressing a function at the National Academy of Direct Taxes (NADT), Mukherjee said more than three-fourths of business transactions nowadays took place through the units of...
More »In the ‘pharmacy of the world’ -PT Jyothi Datta
-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...
More »The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri
-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »The Cost of Drugs: Beyond the Supreme Court Order -Sanjay Nagral
-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...
More »
